The implementation of nanotechnology addressed two critical limitations: poor aqueous solubility of both CYP and PTX, which traditionally restricts bioavailability, and enhanced tumor-targeted delivery through the EPR effect. The gene discussed is PPIG; the disease is neoplasm.